Business
Kelyniam Global Releases Q1 Financials, Announces Licensing Agreement with Bioplate for Osteopore Products
Kelyniam Global Releases Q1 Financials, Announces Licensing Agreement with Bioplate for Osteopore Products.
About this update from Kelyniam Global, Inc.
[{"type":"text","content":"\n\n\n\nKelyniam Global Releases Q1 Financials, Announces Licensing Agreement with Bioplate for Osteopore Products\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nKelyniam Global Releases Q1 Financials, Announces Licensing Agreement with Bioplate for Osteopore Products\nPR Newswire\nCANTON, Conn., May 22, 2023\n\n\n\nCANTON, Conn., May 22, 2023 /PRNewswire/ -- Kelyniam Global (OTC: KLYG), a leading maker of custom cranial implants, today announced results for its quarter ended March 31, 2023.\n\"I'm pleased to announce that Kelyniam has expanded our licensing agreement with Bioplate to allow the Company to sell Osteopore products in select markets in the U.S.  Kelyniam will have the opportunity to sell these unique, high quality products in high volume hospitals in New York, New Jersey, Massachusetts, Maryland and Florida,\" said Ross Bjella, Kelyniam's CEO.  \"Osteostrip, Osteoplug, and Osteomesh have unique osteo-integrative properties that solve unmet clinical needs.  Adding innovative new products like these is part of our strategy to diversify the Kelyniam product line within the cranio-facial market.\"\nThis agreement expands the current agreement between Bioplate and Kelyniam for the distribution of the Bioplate product line of surgical plates and screws. Osteopore Ltd (ASX: OSX) is an Australian and Singapore-based company commercializing products to facilitate natural bone healing. Osteopore implants are manufactured using patented technology that dissolves over time, leaving only natural, healthy bone tissue. This significantly reduces complications commonly associated with permanent bone implants, making the implants suitable for U.S. surgeons.\nKelyniam's revenue dipped slightly in the quarter associated with below-expectation January sales.  Sales in February and March rebounded significantly but not sufficiently to overcome the earlier drop measured against prior year's quarter. Monthly sales can vary over the year and variability can be expected due to normal market conditions, including weat...